Company Announcement
- At Genmab A/S' Annual General Meeting held today March 19, 2026, the Annual Report for 2025 was approved
- Discharge was given to the Board of Directors and the Executive Management and the year's profit was carried forward
- The 2025 Compensation Report was approved
- Six members of the Board of Directors were re-elected
- Deloitte was re-elected as the auditor of the Company
- The proposal from the Board of Directors to reduce the Company's share capital with nominally DKK 1,900,000 by cancellation of the Company's holding of shares was adopted
COPENHAGEN, Denmark; March 19, 2026 - Genmab A/S (Nasdaq: GMAB) held its Annual General Meeting, today at the Copenhagen Marriott Hotel, Copenhagen, Denmark. At the meeting, Deirdre P. Connelly, Chair of the Board of Directors gave - on behalf of the Board of Directors - a report on the Company's activities during the past year. Chief Executive Officer Dr. Jan van de Winkel presented the Company's plans for 2026, and Chief Financial Officer Mr. Anthony Pagano presented the Annual Report for 2025 endorsed by the auditors. The report was approved, and discharge was given to the Board of Directors and the Executive Management.
It was decided that the year's profit of USD 963 million be carried forward by transfer to retained earnings, as stated in the Annual Report.
The 2025 Compensation Report was approved.
Ms. Deirdre P. Connelly, Ms. Pernille Erenbjerg, Mr. Rolf Hoffmann, Ms. Elizabeth O'Farrell, Dr. Paolo Paoletti and Dr. Anders Gersel Pedersen were re-elected to the Board of Directors for a one-year period.
Deloitte Statsautoriseret Revisionspartnerselskab was re-elected as the Company's auditor.
The General Meeting adopted the proposal from the Board of Directors to reduce the Company's share capital for the purpose of cancelling treasury shares.
The proposal from the Board of Directors on the Board of Directors' remuneration for 2026 was withdrawn. A proposal will be put forward in due course for consideration by shareholders.
About Genmab
Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody-drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab's science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients.
Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com?and follow us on LinkedIn and X.
Contact:
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com
This Company Announcement contains forward looking statements. The words "believe," "expect," "anticipate," "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab's most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.
Genmab A/S and/or its subsidiaries own the following trademarks: Genmab- ; the Y-shaped Genmab logo- ; Genmab in combination with the Y-shaped Genmab logo- ; HuMax- ; DuoBody- ; HexaBody- ; DuoHexaBody- , HexElect- and KYSO-
Company Announcement no. 17
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122
Genmab A/S
Carl Jacobsens Vej 30
2500 Valby
Denmark
